FDA approves Aurobindo’s Abilify generic

DAYTON, N.J. — Aurobindo Pharmma on Monday announced that it had received FDA approval for its generic version of Otsuka Pharmaceuticals’ Abilify (aripiprazole) tablets. The drug is an atypical anipsychotic intended to treat schizophrenia and bipolar disorder.

Aurobindo’s aripiprazole will be available in 2-, 5-, 10-, 15-, 20-, and 30-mg tablets. Abilify had U.S. sales in the twelve months ended August 2015 of $7.3 billion, according to IMS Health Data.